celecoxib has been researched along with Neuroblastoma in 12 studies
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "9 mg/kg/dose) irinotecan (CPT-11) and simultaneous low-dose (5 mg/kg/dose) celecoxib, a cyclooxygenase-2 inhibitor, administered for 20 consecutive days, had synergistic antitumor activity against human neuroblastoma xenografts in mice." | 7.79 | Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts. ( Fukushima, T; Kaneko, M; Kaneko, S, 2013) |
| "The cytotoxicity effects of VPA, celecoxib, and combined VPA and celecoxib treatment on neuroblastoma cells were studied." | 7.77 | Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. ( Chen, Y; Tsai, YH; Tseng, SH, 2011) |
| "Neuroblastoma cell cytotoxicity of chemotherapeutic drugs in combination with celecoxib was examined." | 7.74 | Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. ( Eksborg, S; Fuskevåg, OM; Gleissman, H; Johnsen, JI; Kogner, P; Ponthan, F; Redfern, CP; Segerström, L; Sveinbjörnsson, B; Wickström, M, 2007) |
| " Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months." | 5.24 | Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. ( Belogurova, M; Berthold, F; Ernst, A; Hömberg, M; Mazanek, P; Proleskovskaya, I; Sterba, J, 2017) |
| "9 mg/kg/dose) irinotecan (CPT-11) and simultaneous low-dose (5 mg/kg/dose) celecoxib, a cyclooxygenase-2 inhibitor, administered for 20 consecutive days, had synergistic antitumor activity against human neuroblastoma xenografts in mice." | 3.79 | Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts. ( Fukushima, T; Kaneko, M; Kaneko, S, 2013) |
| "Neuroblastoma is the single most common and deadly tumor of childhood and is often associated with therapy resistance." | 1.32 | Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. ( Elfman, L; Johnsen, JI; Kogner, P; Lindskog, M; Orrego, A; Pettersen, I; Ponthan, F; Sveinbjörnsson, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthold, F | 1 |
| Hömberg, M | 1 |
| Proleskovskaya, I | 1 |
| Mazanek, P | 1 |
| Belogurova, M | 1 |
| Ernst, A | 1 |
| Sterba, J | 3 |
| Bell, E | 1 |
| Ponthan, F | 3 |
| Whitworth, C | 1 |
| Tweddle, DA | 1 |
| Lunec, J | 1 |
| Redfern, CP | 2 |
| Wickström, M | 2 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 3 |
| Sandén, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Kool, M | 1 |
| Kogner, P | 3 |
| Baryawno, N | 1 |
| Johnsen, JI | 3 |
| Evageliou, NF | 1 |
| Haber, M | 1 |
| Vu, A | 1 |
| Laetsch, TW | 1 |
| Murray, J | 1 |
| Gamble, LD | 1 |
| Cheng, NC | 1 |
| Liu, K | 1 |
| Reese, M | 1 |
| Corrigan, KA | 1 |
| Ziegler, DS | 1 |
| Webber, H | 1 |
| Hayes, CS | 1 |
| Pawel, B | 1 |
| Marshall, GM | 1 |
| Zhao, H | 1 |
| Gilmour, SK | 1 |
| Norris, MD | 1 |
| Hogarty, MD | 1 |
| Kaneko, M | 2 |
| Kaneko, S | 2 |
| Suzuki, K | 1 |
| Redova, M | 2 |
| Chlapek, P | 2 |
| Loja, T | 1 |
| Zitterbart, K | 2 |
| Hermanova, M | 2 |
| Veselska, R | 2 |
| Chen, Y | 1 |
| Tsai, YH | 1 |
| Tseng, SH | 1 |
| Fukushima, T | 1 |
| Lindskog, M | 1 |
| Pettersen, I | 1 |
| Elfman, L | 1 |
| Orrego, A | 1 |
| Pyrko, P | 1 |
| Soriano, N | 1 |
| Kardosh, A | 1 |
| Liu, YT | 1 |
| Uddin, J | 1 |
| Petasis, NA | 1 |
| Hofman, FM | 1 |
| Chen, CS | 1 |
| Chen, TC | 1 |
| Schönthal, AH | 1 |
| Gleissman, H | 1 |
| Fuskevåg, OM | 1 |
| Segerström, L | 1 |
| Eksborg, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)[NCT02641314] | Phase 2 | 26 participants (Anticipated) | Interventional | 2016-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for celecoxib and Neuroblastoma
| Article | Year |
|---|---|
Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
Topics: Administration, Metronomic; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; | 2017 |
11 other studies available for celecoxib and Neuroblastoma
| Article | Year |
|---|---|
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.
Topics: Animals; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fem | 2014 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line | 2016 |
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Celecoxib; Cell Proliferation; Child, Pres | 2009 |
Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines.
Topics: Apoptosis; Caffeic Acids; Celecoxib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Shape; | 2010 |
Enhancement of ATRA-induced differentiation of neuroblastoma cells with LOX/COX inhibitors: an expression profiling study.
Topics: Brain Neoplasms; Caffeic Acids; Celecoxib; Cell Differentiation; Cyclooxygenase Inhibitors; Enzyme I | 2010 |
Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; | 2011 |
Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Celecoxib; Cell Li | 2013 |
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosi | 2004 |
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Celecoxib; Cell Survival; Dose-Response Rel | 2006 |
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib | 2007 |